PRECISION BIOSCIENCES INC

Listed Company

DTILCIK 0001357874NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends May 21

Period

FY 2025

Revenue

$34.26M

Net Income

$-45.72M

Total Assets

$154.42M

Equity

$92.25M

Shares Out

24.73M

Op. Cash Flow

$-65.84M

Business

PRECISION BIOSCIENCES INC is a clinical-stage gene editing company that develops in vivo gene editing therapies using its proprietary ARCUS platform. Its main products and services include ARCUS-based nuclease therapies and programs such as PBGENE-HBV, PBGENE-3243, PBGENE-DMD and other insertion/excision candidates, together with licensing, collaborations and IP licensing activities. The company operates through key segments of wholly‑owned in vivo gene editing programs, partnered development programs and licensing/immunotherapy assets. It conducts clinical and preclinical development across North America, Europe, Asia and Oceania and works with global biopharma partners and delivery channels (AAV, LNP).

Summary from filing dated 2025-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	34	69	49	25	116
Research and development	54	60	53	46	115
General and administrative	32	35	39	41	40
Total operating expenses	86	95	92	87	155
Operating loss	−52	−26	−44	−62	−39
Loss from equity method investment	−5	−1	−5	−2	184,000
(Loss) gain on changes in other fair value adjustments	−3	258,000	1	−510,000	—
Gain on change in fair value of warrant liability	11	30	—	—	—
Interest expense	1	2	—	—	—
Interest income	4	7	8	3	208,000
Loss on disposal of assets	−421,000	−436,000	−461,000	−30,000	−26,000
Impairment charges	−36,000	0	—	−11	—
Total other income	6	33	1	−11	9
(Loss) income from continuing operations	−47	7	−43	−73	—
Gain from discontinued operations	885,000	0	−19	−39	—
Net (loss) income	−46	7	−61	−112	−31
Basic (in USD per shares)	−3.56	1.05	−15.96	−38.1	−0.52
Diluted (in USD per shares)	−3.56	1.04	−15.96	−38.1	−0.52
Basic (in shares)	13	7	4	3	59
Diluted (in shares)	13	7	4	3	59

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	111	86	117	190	144
Accounts receivable	0	229,000	901,000	720,000	488,000
Marketable securities	5	413,000	—	—	—
Prepaid expenses	3	6	6	6	17
Assets held for sale	0	169,000	487,000	—	—
Contract asset	0	1	—	—	—
Other current assets	45,000	369,000	419,000	1	169,000
Total current assets	119	95	136	199	162
Restricted cash	26	23	—	—	—
Property, equipment, and softwarenet	1	3	6	12	25
Intangible assetsnet	1	622,000	400,000	731,000	2
Right-of-use assetsnet	6	7	8	2	4
Investment in equity securities	744,000	3	3	3	3
Note receivablenet	0	5	5	7	7
Other assets	206,000	221,000	225,000	226,000	5
Total assets	154	136	160	238	211
Accounts payable	296,000	1	3	653,000	1
Accrued compensation	5	5	5	5	7
Accrued research and development expenses	2	2	2	2	—
Deferred revenue	0	3	12	46	21
Lease liabilities	2	1	1	2	2
Other current liabilities	649,000	989,000	2	745,000	977,000
Current liabilities of discontinued operations	0	1	3	3	—
Total current liabilities	9	15	50	60	36
Loan payable	22	22	—	—	—
Deferred revenue	0	23	73	83	67
Lease liabilities	5	6	8	1	5
Warrant liability	16	3	—	—	—
Contract liabilities	10	10	10	10	10
Other noncurrent liabilities	259,000	194,000	128,000	201,000	44,000
Total liabilities	62	80	141	178	120
Commitments and contingencies (Note 14)	—	—	—	—	—
Preferred stock: $0.0001 par value 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024	0	0	—	—	—
Common stock: $0.000005 par value 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 24,115,346 shares issued and 24,088,425 shares outstanding as of December 31, 2025; 8,229,730 shares issued and 8,202,715 shares outstanding as of December 31, 2024	1,000	1,000	1,000	1,000	—
Additional paid-in capital	621	540	509	490	409
Accumulated deficit	−528	−482	−490	−428	−317
Treasury stock	−952,000	−952,000	−952,000	−952,000	−952,000
Total stockholders equity	92	56	19	60	91
Total liabilities and stockholders equity	154	136	160	238	211

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net (loss) income	−46	7	−61	−112	−31
Depreciation and amortization	2	3	7	8	9
Share-based compensation	10	13	14	19	17
(Gain) loss on disposal of assets	421,000	436,000	563,000	106,000	26,000
Issuance of common stock in exchange for services	259,000	0	—	—	—
Non-cash interest expense	186,000	249,000	368,000	295,000	59,000
Amortization of right-of-use assets	1	1	1	1	1
Loss (gain) on changes in other fair value adjustments	3	−258,000	−1	510,000	—
Gain from disposal of business	−855,000	0	—	—	—
Amortization of discount on note receivable	−682,000	−695,000	−515,000	−355,000	−13,000
Gain on change in fair value of warrant liability	−11	−30	—	—	—
Prepaid expenses	3	−464,000	1	−962,000	6
Marketable securities	−5	2	—	—	—
Convertible note receivable	0	10	—	—	—
Accounts receivable	229,000	672,000	−181,000	−232,000	10
Contract asset	1	−1	—	—	—
Other assets and other current assets	339,000	−262,000	2	1	−3
Accounts payable	−737,000	−2	2	153,000	867,000
Other liabilities and other current liabilities	−2	−2	−724,000	−2	1
Deferred revenue	−26	−59	−44	27	−3
Lease liabilities	−1	−1	−946,000	−2	−2
Net cash used in operating activities	−66	−58	−84	−46	−11
Purchases of property, equipment and software	−85,000	−250,000	−2	−3	−5
Purchases of intangibles assets	−615,000	−25,000	−321,000	—	−750,000
Proceeds from sale of equipment	66,000	60,000	107,000	—	—
Net cash used in investing activities	−634,000	−215,000	6	−3	−6
Proceeds from employee stock purchase plan	218,000	249,000	370,000	443,000	804,000
Proceeds from offering of common stock and warrants through underwritten offering, net of issuance costs	70	37	—	—	—
Proceeds from issuance of common stock through ATM facility, net of issuance cost	24	12	—	—	—
Proceeds from offering of common stock to collaboration partners and licensees	1	905,000	—	25	35
Repayment of revolving credit facility	0	−23	—	—	—
Borrowings from term loan debt facility, net of issuance costs paid to lender	0	22	—	—	2
Net cash provided by financing activities	95	50	5	95	71
Net increase (decrease) in cash, cash equivalents and restricted cash	29	−8	−73	46	54
Property, equipment and software additions included in accounts payable, accrued expenses and other current liabilities	0	48,000	14,000	103,000	103,000
Intangible asset additions included in accounts payable and accrued expenses and other current liabilities	300,000	250,000	—	—	—
Cash paid for interest	1	2	2	824,000	68,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro